Is PT-141 (Bremelanotide) Legal in Tennessee?

What Is PT-141 (Bremelanotide)?

PT-141 is the research name for bremelanotide, a cyclic heptapeptide that acts as a non-selective melanocortin receptor agonist, primarily at MC1R, MC3R, and MC4R. Unlike phosphodiesterase-5 inhibitors such as sildenafil, bremelanotide acts centrally on neural pathways regulating sexual motivation rather than directly on vascular smooth muscle. That distinction matters clinically because it addresses desire, not just physical response.

Mechanism of Action

Bremelanotide binds MC4 receptors in the hypothalamus, modulating dopaminergic tone in circuits associated with sexual appetite. Animal and early human studies identified this central pathway in the early 2000s, eventually motivating the phase-III program that led to FDA approval. The receptor pharmacology is described in the approved prescribing information filed under NDA 210557.

Approved Indication

The FDA approved bremelanotide on August 23, 2019, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approval letter and labeling confirm this indication. HSDD is defined in the Diagnostic and Statistical Manual of Mental Disorders as persistently deficient or absent sexual desire causing marked distress.

Use Beyond the Label

Clinicians sometimes prescribe bremelanotide off-label for male sexual dysfunction, including erectile dysfunction with a psychogenic component. Off-label prescribing is a lawful medical practice in the United States when supported by clinical judgment. The FDA's own guidance on off-label use confirms practitioners retain the discretion to prescribe approved drugs outside the labeled indication.

Federal Legal Status of Bremelanotide

Bremelanotide holds full FDA approval. It is not listed on any DEA schedule under the Controlled Substances Act. This combination places it in the same legal category as most other prescription medications: legal to prescribe, dispense, and possess with a valid prescription anywhere in the United States.

FDA Approval History

The key phase-III trials supporting approval were RECONNECT Study 1 and Study 2. In the pooled population of 1,267 premenopausal women with HSDD, bremelanotide 1.75 mg produced statistically significant improvements on the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire at week 24 compared with placebo (P<0.001 for both co-primary endpoints). The primary RECONNECT data were published in Obstetrics and Gynecology in 2018, forming the evidentiary backbone of the NDA.

DEA Scheduling

The Drug Enforcement Administration assigns schedules (I through V) based on abuse potential, accepted medical use, and dependence liability. Bremelanotide has accepted medical use (FDA approval) and no identified high-abuse profile. The DEA has not scheduled it. A Tennessee patient possessing an injectable bremelanotide pen prescribed by a licensed practitioner faces no federal controlled-substance liability.

FDA Bulk-Drug Compounding Guidance

The FDA maintains a list of bulk drug substances that compounding pharmacies may use under section 503A of the Federal Food, Drug, and Cosmetic Act. Bremelanotide is not on the FDA's 503A Bulks List as a nominated and evaluated substance with positive status. Because the reference listed drug (Vyleesi) exists, compounding pharmacies cannot routinely compound copies under 503A without a finding of clinical necessity. Compounding that produces a copy of an approved drug solely for cost reasons falls outside 503A protections. Prescribers and patients should confirm their pharmacy's compliance posture before ordering a compounded formulation.

Tennessee State Law: What Applies to PT-141

Tennessee has not enacted any statute or administrative rule that specifically restricts bremelanotide beyond federal prescription-drug requirements. The drug is governed in Tennessee by the same rules that apply to any legend drug.

Tennessee Pharmacy Act

The Tennessee Pharmacy Act (Tenn. Code Ann. Title 63, Chapter 10) requires that prescription drugs be dispensed only pursuant to a valid prescription from a licensed practitioner. A Tennessee-licensed pharmacy filling a bremelanotide prescription issued by a licensed MD, DO, NP, or PA operates entirely within state law. The Tennessee Board of Pharmacy oversees compliance, and no board advisory or declaratory order has identified bremelanotide as a substance of concern.

Tennessee Medical Practice Act

Under Tenn. Code Ann. Title 63, Chapter 6, physicians may prescribe any non-scheduled FDA-approved drug that falls within the bounds of accepted medical practice. Prescribing bremelanotide for HSDD in a premenopausal woman maps directly onto the FDA-approved indication. Off-label prescribing for other diagnoses is permissible when documented with appropriate clinical rationale. The Endocrine Society's clinical practice guidelines on female sexual dysfunction provide a published framework supporting such decisions.

Tennessee Compounding Pharmacy Rules

Tennessee-licensed 503A compounding pharmacies operate under both state Board of Pharmacy rules and federal FDCA requirements. Because the FDA has not evaluated bremelanotide for the 503A bulks list as a substance appropriate for bulk compounding (given the existence of Vyleesi), Tennessee 503A pharmacies should approach compounded bremelanotide cautiously. A 503B outsourcing facility operating under current good manufacturing practice has a different regulatory pathway but still cannot mass-produce copies of an approved drug without office-use compounding exceptions. Patients who receive a compounded formulation should ask their prescriber whether clinical necessity has been documented in the chart.

How to Get PT-141 (Bremelanotide) in Tennessee

Obtaining bremelanotide legally in Tennessee requires a valid prescription. The process is straightforward for most patients, and telehealth has made access considerably more convenient than it was when only in-office visits were possible.

Step 1: Clinical Evaluation

A qualified clinician conducts a history and physical to confirm the diagnosis of HSDD or the off-label indication being treated. For HSDD, the International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care guidelines recommend ruling out relationship factors, mood disorders, hormonal deficiency, and medication side effects before initiating pharmacotherapy. Tennessee practitioners are expected to document this differential assessment.

Step 2: Prescription from a Licensed Tennessee Practitioner

Any Tennessee-licensed prescriber may write for bremelanotide. Tennessee NPs with full practice authority (effective since 2023 for those meeting experience requirements) and PAs with a supervision agreement may also prescribe. The prescription must specify the dose (1.75 mg per the FDA label), route (subcutaneous), frequency (no more than one dose per 24 hours, maximum eight doses per month per prescribing information), and any relevant clinical indication.

Step 3: Dispensing at a Licensed Pharmacy

The FDA-approved brand Vyleesi is dispensed at retail and specialty pharmacies. Because it is not a controlled substance, no special DEA order form or triplicate prescription is required in Tennessee. A standard written or electronic prescription is sufficient. Patients using telehealth services may receive the prescription electronically sent to a mail-order or local pharmacy.

Step 4: Telehealth Options for Tennessee Residents

Tennessee joined the Interstate Medical Licensure Compact (IMLC), enabling out-of-state physicians holding a compact privilege to treat and prescribe for Tennessee patients. IMLC participation data confirm Tennessee's active membership. Telehealth platforms specializing in sexual health and hormone therapy may employ IMLC-licensed physicians who can evaluate Tennessee patients remotely, issue a lawful prescription, and route it to a pharmacy of the patient's choice.

The HealthRX PT-141 Access Framework for Tennessee Patients

The following decision tree summarizes the pathway a Tennessee patient should follow:

1. Consult a Tennessee-licensed or IMLC-privileged prescriber (in-person or telehealth).
2. Complete a documented clinical evaluation including hormonal panel, medication review, and validated distress scale (e.g., FSDS-R).
3. Receive a written or electronic prescription for bremelanotide 1.75 mg subcutaneous.
4. Confirm dispensing pharmacy holds a valid Tennessee pharmacy permit or is licensed in the state from which it ships.
5. If considering a compounded formulation, ask the prescriber to document clinical necessity and confirm the compounding pharmacy's 503A compliance posture with the FDA bulks list.
6. Store the auto-injector as labeled (refrigerated or room temperature for up to 30 days per prescribing information).

Clinical Evidence Supporting Bremelanotide Use

Understanding the evidence base helps both patients and prescribers place the drug in proper context.

The RECONNECT Phase-III Trials

RECONNECT comprised two identical double-blind, placebo-controlled, parallel-group trials enrolling a combined 1,267 premenopausal women with HSDD across North American sites. Patients self-administered bremelanotide 1.75 mg subcutaneously as needed, up to 24 weeks. The co-primary endpoints were change from baseline in the FSFI desire domain score and the FSDS-DAO item 13 score. Both trials met their co-primary endpoints (P<0.001). The published results appeared in Obstetrics and Gynecology (2018, 132(1):44-52).

Key Efficacy Numbers

In the pooled RECONNECT analysis, bremelanotide-treated patients showed a mean increase of 0.5 points on the FSFI desire subdomain versus 0.2 points for placebo. On the FSDS-DAO item 13, the active arm improved by 0.3 points versus 0.1 for placebo. These differences, while statistically significant, are modest in absolute terms. Clinicians should counsel patients that response rates vary and that the drug addresses desire-related distress rather than producing a consistent physiological effect on every use.

Safety Profile

The most common adverse events in RECONNECT were nausea (40.0% bremelanotide vs. 1.3% placebo), flushing (20.4% vs. 0%), and headache (11.0% vs. 2.0%). FDA prescribing information contraindicates use in patients with cardiovascular disease, as transient increases in blood pressure (mean 2-4 mmHg systolic, 1-2 mmHg diastolic) were observed. Patients with hypertension should have blood pressure optimized before use.

Comparison with Flibanserin

Flibanserin (Addyi, approved 2015) is the only other FDA-approved pharmacotherapy for HSDD in premenopausal women. Unlike bremelanotide, flibanserin is taken daily and carries a REMS program due to the risk of severe hypotension with alcohol. A 2021 review in the Journal of Sexual Medicine compared patient tolerability profiles of both agents, noting that bremelanotide's as-needed dosing appeals to patients who prefer not to commit to daily medication. Tennessee prescribers have both options available.

Regulatory Gray Areas and Risk Factors to Know

Not every aspect of PT-141 prescribing is black and white. Several areas carry residual regulatory complexity.

Compounded Bremelanotide Sold Online

Websites selling "research-grade" or "peptide-grade" PT-141 powder or solution without requiring a prescription are operating outside federal law. The FDA has issued multiple warning letters to peptide suppliers selling unapproved substances. FDA Warning Letters to compounders are publicly searchable and include actions against unlicensed peptide distributors. Purchasing from these sources exposes Tennessee residents to potential federal FDCA misbranding and adulteration liability, unknown purity, and no clinician oversight.

503B Outsourcing Facilities

A 503B outsourcing facility registered with the FDA may compound bremelanotide for office use without a patient-specific prescription, but only when the conditions in FDCA section 503B are met, including current GMP compliance and FDA registration. Tennessee clinics using 503B-sourced bremelanotide should verify the facility's FDA registration before stocking.

Insurance Coverage

Vyleesi is covered by some commercial insurers but coverage is inconsistent. The list price has historically exceeded $800 per dose. Prior authorization is commonly required. Patients who encounter coverage denials sometimes turn to compounded formulations; that pathway requires careful attention to the 503A compliance issues described above. The National Women's Health Network has published commentary on access disparities for female sexual dysfunction treatments.

What Tennessee Clinicians Should Document

Prescribers in Tennessee face the same documentation standard as in any state. Good clinical records protect both patients and practitioners.

Required Chart Elements

Every bremelanotide prescription should be supported by:

• A confirmed diagnosis of HSDD or a clearly articulated off-label rationale.
• Documentation that contributing medical, psychiatric, and relationship factors have been assessed.
• A note on cardiovascular screening, given the transient blood pressure effect.
• Informed consent including common adverse effects (nausea, flushing).
• The specific dose, route, frequency, and refill limits.

The American College of Obstetricians and Gynecologists (ACOG) has published guidance on female sexual dysfunction that outlines an evaluation framework consistent with these documentation requirements.

Monitoring Recommendations

No mandatory laboratory monitoring is specified in the bremelanotide prescribing information. Blood pressure measurement before the first dose is prudent, given the known transient pressor effect. The FDA label recommends not using bremelanotide in patients with known cardiovascular disease.

Summary of Legal Status by Scenario

| Scenario | Legal in Tennessee? | |---|---| | Branded Vyleesi with valid prescription from TN-licensed prescriber | Yes | | Compounded bremelanotide from TN 503A pharmacy with documented clinical necessity | Potentially yes, with compliance caveats | | Compounded bremelanotide from FDA-registered 503B facility (office use) | Yes, if 503B facility is registered | | "Research peptide" PT-141 purchased online without prescription | No | | Telehealth prescription from IMLC-privileged out-of-state physician | Yes |